ZA200805868B - Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage - Google Patents

Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage

Info

Publication number
ZA200805868B
ZA200805868B ZA200805868A ZA200805868A ZA200805868B ZA 200805868 B ZA200805868 B ZA 200805868B ZA 200805868 A ZA200805868 A ZA 200805868A ZA 200805868 A ZA200805868 A ZA 200805868A ZA 200805868 B ZA200805868 B ZA 200805868B
Authority
ZA
South Africa
Prior art keywords
dha
epa
treating
oxidative damage
pathology associated
Prior art date
Application number
ZA200805868A
Other languages
English (en)
Inventor
Pedrol Joan Carles Domingo
Garcia Jose Antonio Villegas
Original Assignee
Brudy Technology S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brudy Technology S L filed Critical Brudy Technology S L
Publication of ZA200805868B publication Critical patent/ZA200805868B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
ZA200805868A 2005-12-21 2006-12-20 Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage ZA200805868B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200503202A ES2277557B1 (es) 2005-12-21 2005-12-21 Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.

Publications (1)

Publication Number Publication Date
ZA200805868B true ZA200805868B (en) 2009-12-30

Family

ID=38330572

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805868A ZA200805868B (en) 2005-12-21 2006-12-20 Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage

Country Status (13)

Country Link
US (1) US10493008B2 (es)
JP (4) JP2014028830A (es)
CN (1) CN103263406B (es)
DK (1) DK1962825T3 (es)
ES (4) ES2277557B1 (es)
IL (1) IL230165A (es)
MX (1) MX362194B (es)
MY (1) MY148603A (es)
NO (1) NO343220B1 (es)
NZ (2) NZ598529A (es)
PT (1) PT1962825E (es)
UA (1) UA93395C2 (es)
ZA (1) ZA200805868B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
BRPI0924012A2 (pt) 2009-04-17 2019-09-24 Cela Vista Pharmaceuticals Ltd processo para obtenção de uma composição rica em ácidos graxos ômega 3 de um óleo de origem marinha, com um teor de af interior 90 mg/g composição, suplemento nutricional produto alimentar, composição farmacêutica, e, uso de um composto
CN106377533A (zh) * 2016-09-08 2017-02-08 中国海洋大学 一种海参磷脂及其在提高机体运动协调能力制品中的应用
JP2019064955A (ja) * 2017-09-29 2019-04-25 金印株式会社 アミロイドβ耐性増強剤
US11065288B2 (en) 2017-09-29 2021-07-20 Kinjirushi Co., Ltd. Neuron activator
JP6949363B2 (ja) * 2017-09-29 2021-10-13 金印株式会社 ドーパミン産生促進剤
JP6949364B2 (ja) * 2017-09-29 2021-10-13 金印株式会社 神経細胞伸長促進剤
KR102491238B1 (ko) * 2022-02-14 2023-01-26 줄리아 연구소 주식회사 혈관신생 조절 인자들을 포함하는 바이오마커를 이용한 혈관신생 연관 질환 진단용 조성물, 혈관신생 연관 질환 진단을 위한 정보제공방법 및 혈관신생 연관 질환 치료용 물질의 스크리닝 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
US20050027004A1 (en) 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
ATE446101T1 (de) * 1993-06-09 2009-11-15 Martek Biosciences Corp Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
JPH07255417A (ja) * 1994-03-25 1995-10-09 Kanebo Ltd 機能性健康食品
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
EP0823475B1 (en) 1995-04-17 2009-06-17 National Institute of Advanced Industrial Science and Technology Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JP3558423B2 (ja) * 1995-09-11 2004-08-25 旭化成ケミカルズ株式会社 ドコサヘキサエン酸を構成脂肪酸とするリン脂質の製造方法
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
AU3120797A (en) * 1996-05-08 1998-07-31 Weider Nutrition Group, Inc. Structured glycerols and structured phosphatides
DK0935667T3 (da) * 1996-07-23 2007-04-10 Nagase Chemtex Corp Fremgangsmåde til fremstilling af docosahexaensyre og docosapentaensyre
WO1998057628A1 (fr) 1997-06-16 1998-12-23 Nippon Suisan Kaisha, Ltd. Composition capable de supprimer le facteur de risque pendant l'exercice
JPH11239465A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 健常人が運動能力を高める食品
JPH11239464A (ja) * 1997-06-16 1999-09-07 Nippon Suisan Kaisha Ltd 運動時の危険因子除去能を有する組成物
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2002040014A (ja) * 2000-07-19 2002-02-06 Nippon Steel Corp 炭素含有耐火物の耐摩耗性、耐食性及び耐酸化性の評価方法
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
ATE398445T1 (de) * 2002-03-28 2008-07-15 Alcon Inc Co-perlchen von dha und rosmarin und verwendungsverfahren
AR039170A1 (es) * 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
JP4268473B2 (ja) * 2002-08-07 2009-05-27 花王株式会社 油脂組成物
DE20214827U1 (de) * 2002-09-25 2003-02-20 Bartz Volker Leistungsförderer für Sportler zur oralen Einnahme
DE10244907A1 (de) * 2002-09-25 2004-04-15 Volker Bartz Leistungsförderer für Sportler zur oralen Einnahme bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA/DHA und L-Carnitin als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
EP1551382A4 (en) * 2002-09-27 2007-01-24 Martek Biosciences Corp PROPHYLACTIC TREATMENT WITH DOCOSAHEXAENIC ACID FOR PATIENTS WITH SUBCLINIC INFLAMMATION
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
US20040209953A1 (en) 2002-12-06 2004-10-21 Wai Lee Theresa Siu-Ling Glyceride compositions and methods of making and using same
US7041840B2 (en) 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
JP2005000033A (ja) * 2003-06-10 2005-01-06 Shinbijuumu:Kk 食品
GB0314624D0 (en) * 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
WO2005013908A2 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7842722B2 (en) 2003-12-19 2010-11-30 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US20050163873A1 (en) 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
WO2006077495A1 (en) 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases
FR2882894B1 (fr) 2005-03-11 2009-04-03 Larena Sa Composition alimentaire suppletive
ES2264886B1 (es) 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
AU2006327064B2 (en) 2005-12-21 2012-04-26 Brudy Technology, S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.

Also Published As

Publication number Publication date
ES2315125B1 (es) 2009-12-30
NO343220B1 (no) 2018-12-10
JP6556640B2 (ja) 2019-08-07
US20160151320A1 (en) 2016-06-02
NZ598529A (en) 2013-12-20
UA93395C2 (ru) 2011-02-10
ES2277557B1 (es) 2008-07-01
MX362194B (es) 2019-01-08
NO20171318A1 (no) 2008-09-19
ES2315125A1 (es) 2009-03-16
JP2014028830A (ja) 2014-02-13
IL230165A (en) 2016-11-30
CN103263406B (zh) 2015-03-25
CN103263406A (zh) 2013-08-28
NZ598530A (en) 2013-03-28
DK1962825T3 (da) 2014-06-30
ES2316263A1 (es) 2009-04-01
PT1962825E (pt) 2014-07-04
JP2016128494A (ja) 2016-07-14
ES2315124A1 (es) 2009-03-16
ES2277557A1 (es) 2007-07-01
JP2015157838A (ja) 2015-09-03
JP2017095496A (ja) 2017-06-01
US10493008B2 (en) 2019-12-03
MY148603A (en) 2013-05-15
ES2316263B1 (es) 2009-12-30
ES2315124B1 (es) 2009-12-30

Similar Documents

Publication Publication Date Title
IL192154A0 (en) Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
IL237408B (en) Methods to reduce damage from oxidation
IL230165A (en) Medications containing epa, dha or dha derived from epa for the treatment of cell oxidation damage pathology
EP1984081A4 (en) PROCESS FOR OXIDATIVE TREATMENT
IL191379A (en) sewage care
EP1966915A4 (en) REDUCTION OF TUNING TIME
IL189775A0 (en) Ppar active compounds
ZA200705825B (en) Diaper with umbilical feature
IL183889A0 (en) Treatment method
EP1960951A4 (en) CONTENT OF THE TELEPHONE BOOK
TWI319606B (en) Inductor
EP1728319A4 (en) NON-LINEAR FILTERS OF LOW COMPLEXITY
PL1759676T3 (pl) Bandaż dziany
EP1872788A4 (en) TOPICAL AGENT FOR THE TREATMENT OF WOUNDS
IL176829A0 (en) Composition for treating pathology associated with msrv/herv-w
GB0512345D0 (en) Oxidation process
ZA200704610B (en) Treatment apparatus
EP1937581A4 (en) DEVICE FOR TRANSPORTING CHAINS
IL184330A0 (en) Treatment apparatus
GB0520611D0 (en) Overflow preventative
GB2426752B (en) Lifting apparatus
EP2111205A4 (en) LEG LIFT
EP1845971A4 (en) METHOD FOR THE TREATMENT OF CELL DAMAGE
GB0515383D0 (en) Lifting apparatus
GB0523291D0 (en) Treatment table